Quote 1 from article 1:

NURR1 activates genes associated with the survival of the dopamine neurons, such as the receptor c-RET. cRET is the receptor for the neurotrophic factor GDNF (or Glial cell-derived neurotrophic factor) which has had a long history associated with Parkinson’s disease

Quote 2 from article 1:

NURR1 is very important for activating the transcription of a lot of genes that are required for making and maintaining a dopamine neuron.

The researchers of above study 2 tested the cancer drug bexarotene (also known as Targretin) on rats finding that is the dopamine neurons were restored in rats.

bexarotene use on rats to restore dopamine neurons

The researchers in another study 3 successfully screened a large FDA-approved drug library to identify NURR1-activating compounds. They identified three:

  • amodiaquine (anti-malaria drug)
  • chloroquine (anti-malaria drug)
  • glafenine (a pain-relieving drug)

All those drugs bexarotene, amodiaquine, chloroquine and glafenine have all been FDA-approved for use on human. So, why are they not directly tested on human with Parkinson's disease?

1 https://scienceofparkinsons.com/2017/10/21/are-we-getting-nurr-to-the-end-of-parkinsons-disease/
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837375/
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507186/

| |

Your Answer

By clicking “Post Your Answer”, you agree to our terms of service, privacy policy and cookie policy

Browse other questions tagged or ask your own question.